EPI Data Slicer
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
EPI Data Slicer
EPI Data Slicer
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
We expect the ulcerative colitis (UC) market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio,…
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer